

International Symposium on TRIGLYCERIDES, METABOLIC DISORDERS, AND CARDIOVASCULAR DISEASE

POSTER SESSIONS

NOTE: THE AUTHOR LISTED IN BOLD TYPE IS THE PRESENTING AUTHOR.

POSTER SESSION 1 (Posters 1-7)

EPIDEMIOLOGY OF HYPERTRIGLYCERIDEMIA AND CVD

•

POSTER SESSION 2 (Posters 8-19)

HYPERTRIGLYCERIDEMIA, INSULIN RESISTANCE, AND METABOLIC SYNDROME

•

POSTER SESSION 3 (Posters 20-25)

DYSLIPIDEMIA IN TYPE 2 DIABETES

•

POSTER SESSION 4 (Posters 26-28)

LOW HDL SYNDROME

•

POSTER SESSION 5 (Posters 29-34)

OVERWEIGHT AND OBESITY

•

POSTER SESSION 6 (Posters 35-50)

DIABETES, LIPIDS, AND LIPOPROTEINS

•

POSTER SESSION 7 (Posters 51-63)

TRIGLYCERIDE-RICH LIPOPROTEINS, INFLAMMATION, AND ATHEROSCLEROSIS

•

POSTER SESSION 8 (Posters 64-79)

FATTY ACIDS

•

POSTER SESSION 9 (Posters 80-114)

DRUGS AFFECTING LIPID METABOLISM

•

Posters will be on display for the duration of the Symposium.

One author per poster will be available for discussion at the poster site during these times:

Poster Discussions and Reception *Friday, July 11 – 6:00 p.m. – 7:30 p.m.*
Poster Discussions *Saturday, July 12 – 12:30 p.m. – 2:00 p.m.*

*The Young Investigator Awards will be announced and presented during the
Poster Discussions and Reception on Friday, July 11 from 6:00 p.m. to 7:30 p.m.*

POSTER SESSION 1

◆
EPIDEMIOLOGY OF
HYPERTRIGLYCERIDEMIA AND CVD

Poster No.		Abstract Book Page Ref.
1.	ANGIOTENSIN CONVERTING ENZYME (ACE) GENE POLYMORPHISM IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) Aronov D. , Limborskaya S., Yufereva Y., Slominsky P., Tupitsina T., Zhidko N. (Moscow, Russia)	33
2.	TRIGLYCERIDE CHANGES RELATED TO BMI MODIFICATION OVER TIME IN A GROUP OF MEDITERRANEAN WOMEN Gentile M. , Rubba F., Mattiello A., Celentano E., Galasso R., Ciardullo A.V., Santucci de Magistris M., Del Pezzo M., Rubba P., Panico S. (Naples, Italy)	33
3.	RISK OF MORTALITY FROM CHD OF FEMALES AGED 55 - 64 YEARS IS ASSOCIATED WITH TRIGLYCERIDES STRONGER THAN WITH CHOLESTEROL Margeviciene L., Cerniauskiene L.R., Luksiene D.K. , Tamosiunas A. (Kaunas, Lithuania)	33
4.	MENSTRUAL CYCLE LENGTH AND BLOOD LIPIDS IN A COHORT OF MEDITERRANEAN WOMEN Rubba F. , Mattiello A., Celentano E., Galasso R., Ciardullo A.V., Gentile M., Santucci de Magistris M., Del Pezzo M., Triassi M., Rubba P., Panico S. (Naples, Italy)	61
5.	THE COMBINED EFFECTS OF DIABETES AND CORONARY ATHEROSCLEROSIS ON THE SHORT TERM RISK OF VASCULAR EVENTS Saely C.H. , Aczel S., Marte T., Langer P., Drexel H. (Feldkirch, Austria)	33
6.	LOW LDL CHOLESTEROL IN DIABETIC PATIENTS WITH CORONARY ATHEROSCLEROSIS Drexel H., Saely C.H. , Aczel S., Langer P., Marte T., Moll W. (Feldkirch, Austria)	34
7.	PREVALENCE OF MAIN CARDIOVASCULAR RISK FACTORS IN POLAND IN 2002. RESULTS OF NATIONWIDE STUDY NATPOL III PLUS Zdrojewski T. , Szpakowski P., Bandosz P., Manikowski A., Jakubowski Z., Bautembach S., Wyrzykowski B. (Gdansk and Sopot, Poland)	34

POSTER SESSION 2

◆
HYPERTRIGLYCERIDEMIA, INSULIN RESISTANCE,
AND METABOLIC SYNDROME

Poster No.		Abstract Book Page Ref.
8.	BODY FAT AND C-REACTIVE PROTEIN LEVELS IN HEALTHY NON-OBESE MEN Bo M. , Raspo S., Morra F., Isaia G., Cassader M., Fabris F. (Turin, Italy)	34
9.	BODY MASS INDEX, INSULIN RESISTANCE MARKERS, IN A PORTUGUESE POPULATION SAMPLE FOR CARDIOVASCULAR PREVENTION Faleiro L.L. , Martins M.C., Fonseca A., Rodrigues M.O. (Lisbon, Portugal)	34
10.	ASSOCIATION OF DYSLIPIDEMIA AND SKIN MICROVASCULAR DYSFUNCTION IN OVERWEIGHT SUBJECTS Genoud M. , Morin D., Waeber G., Darioli R., Waeber B., Giusti V., Mooser V., Hayoz D., Feihl F. (Lausanne, Switzerland and Philadelphia, PA, USA)	35
11.	CORONARY CALCIFICATION IN THE METABOLIC SYNDROME: AN ANCILLARY STUDY TO THE WOMEN'S HEALTH INITIATIVE Hsia J. , Burt J., Prasad A., Klouj A. (Washington, DC, USA)	35
12.	ROLE OF LIPID DISTURBANCES IN THE DEVELOPMENT OF GLOBAL RISK OF METABOLIC SYNDROME Mamedov M.N. (Moscow, Russia)	35
13.	THE METABOLIC SYNDROME, AN UNDER RECOGNIZED, UNDER TREATED EPIDEMIC Nash D.T. (Syracuse, NY, USA)	35
14.	THE IMPORTANCE OF OBESITY IN THE DEVELOPMENT OF MICROANGIOPATHIC COMPLICATIONS OF DIABETES MELLITUS TYPE 2 Popa A.R. , Babes A. (Oradea, Romania)	36
15.	PARAOXONASE-1 LEVELS IN EARLY AND LATE PREGNANCY AND IN FETAL CORD BLOOD AT BIRTH Rodie V.A. , Stewart F.M., Ramsay J.E., Brown E.A., Mackness M.I., Freeman D.J. (Glasgow and Manchester, UK)	36

Poster No.		Abstract Book Page Ref.
16.	METABOLIC SYNDROME, ATHEROGENIC LIPOPROTEIN METABOLIC TRAITS: RELATIONSHIP TO CAD IN YOUNG ADULTS Schaper A. , Akosah K., Barnhart S. (La Crosse, WI, USA)	36
17.	HYPERANDROGENY AS A MANIFESTATION OF METABOLIC SYNDROME Khalimova Z.Yu., Shamansurova Z.M. , Sikiotova I.B., Narimova G.G. (Tashkent, Uzbekistan)	36
18.	MATERNAL METABOLIC RESPONSE TO PREGNANCY DETERMINES NEWBORN METABOLIC CHARACTERISTICS INDEPENDENT OF BOTH MATERNAL AND FETAL ADIPOSITY Stewart F. , Caslake M., Greer I., Ramsay J. (Glasgow, UK)	37
19.	INFLAMMATION, C-REACTIVE PROTEIN AND THE RESISTANCE OF ADIPOCYTES AND MYOCYTES TO INSULIN Parchimovich R.M., Titov V.N. (Moscow, Russia)	37

POSTER SESSION 3

◆
DYSLIPIDEMIA IN TYPE 2 DIABETES

Poster No.		Abstract Book Page Ref.
20.	METABOLIC EFFECTS OF A NEW BETA-ADRENERGIC BLOCKER NEBIVOLOL WITH NO MODULATING ACTIVITY IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES Bondarenko I. , Alexandrov An., Kukhareno S., Solanic U., Dedov I. (Moscow, Russia)	37
21.	GOINO PROCEDURE IMPROVED GLUCOSE METABOLISM AND LIPID PROFILE IN PATIENTS WITH NON INSULIN DEPENDENT DIABETES MELLITUS Goino T. , Kitamura T. (Nagano, Japan)	37
22.	EFFICACY OF ATORVASTATIN AT DIFFERENT STARTING DOSES IN LOWERING LDL-C AND TRIGLYCERIDES IN PATIENTS WITH TYPE 2 DIABETES Hey-Hadavi J. , Sasiela B., Laskey R., Ma J., Yurkovic K. (New York, NY, USA)	38
23.	DIABETES MELLITUS TYPE 2 PATIENTS EXHIBIT MORE PRONOUNCED DECREASE OF TRIGLYCERIDS DURING STATIN THERAPY IN COMPARISON TO NON-DIABETIC ONES Lietava J., Kosmálová V., Křižanová D. , Taliga J. (Bratislava, Slovakia)	38
24.	EFFECT OF DIABETES SPECIALTY CLINIC ON LDL-CHOLESTEROL AND TRIGLYCERIDES OVER 1 YEAR Simmons D.L. (Little Rock, AR, USA)	38
25.	EZETIMIBE ADDED TO ON-GOING STATIN THERAPY IN HIGH RISK HYPERCHOLESTEROLEMIC PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS Tonkon M. , Simons L., Masana L., Shah A., Maccubbin D., Gumbiner B. (Santa Ana, CA and Rahway, NJ, USA, New South Wales, Australia and Reus, Spain)	38

POSTER SESSION 4



LOW HDL SYNDROME

Poster No.		Abstract Book Page Ref.
26.	LOW HDL SYNDROME IN ISCHEMIC HEART DISEASE Kanskaya N.V. , Garganeyeva N.P., Semke V.Ya. (Tomsk, Russia)	39
27.	ROLE OF PEROXIDE MODIFIED LIPOPROTEINS IN LIPID METABOLISM IN ATHEROSCLEROSIS Kanskaya N. , Garganeyeva N.P., Semke V.Ya., Pozdnyakova Ya., Zhavoronok T. (Tomsk, Russia)	39
28.	FASTING TRIGLYCERIDE CONCENTRATION CORRELATES WITH FASTING HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS Kolovou G. , Daskalova D., Bilianou H., Anagnostopoulou K., Hoursalas I., Pilatis N., Petropoulos I., Pavlidis A., Salpea K., Cokkinos D.V. (Athens and Piraeus, Greece)	39

POSTER SESSION 5



OVERWEIGHT AND OBESITY

Poster No.		Abstract Book Page Ref.
29.	SURGICAL MANAGEMENT OF MORBID OBESITY USING LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS Beno P. , Taborsky L., Toberny M., Dvorakova J. (Prague, Czech Republic)	39
30.	DYSLIPIDEMIAS AND NON-LIPID RISK FACTORS IN SUBJECTS WITH ISCHEMIC HEART DISEASE AND ESSENTIAL HYPERTENSION Danilogorskaya J.A. , Zakharova V. (Moscow, Russia)	40
31.	NOVEL METHODOLOGY FOR THE RAPID ISOLATION OF INTERMEDIATE DENSITY LIPOPROTEIN: LIPID AND APOPROTEIN COMPOSITION McFarlane C. , Young I.S., Hare L., McEneny J. (Belfast, UK)	40
32.	COMPARATIVE LEVELS OF LEPTIN UPON HYPOTHALAMIC OBESITY AND IN HEALTHY FERTILE FEMALES Narimova G.D. , Khalimova Z.Yu. (Tashkent, Uzbekistan)	40
33.	ADIPOSE TISSUE EXCESS AS METABOLIC AND CARDIOVASCULAR RISK FACTOR Popa A.R. , Babes A. (Oradea, Romania)	40
34.	WAIST TO HIP RATIO IS A STRONG INDEPENDENT PREDICTOR FOR SHORT TERM CARDIOVASCULAR MORTALITY, PARTICULARLY IN WOMEN Hoefle G., Saely C.H. , Aczel S., Benzer W., Marte T., Langer P., Drexel H. (Feldkirch, Austria)	41

POSTER SESSION 6

DIABETES, LIPIDS, AND LIPOPROTEINS

Poster No.		Abstract Book Page Ref.
35.	EPIDEMIOLOGY OF ATHEROSCLEROSIS PREDICTORS IN SCHOOLCHILDREN BANAT STUDY Boeriu E. , Cucuruz M., Marc M., Cionca L., Vernic C., Serban M. (Timisoara, Romania)	41
36.	LIPIDIC METABOLICAL DISORDER IN DIABETES MELLITUS IN CHILDREN Boeriu E. , Cucuruz M., Marc M., Cionca L., Vernic C., Serban M. (Timisoara, Romania)	41
37.	ELEVATED LEVELS OF LOW-DENSITY-LIPOPROTEIN, HOMOCYSTEINE, AND LIPOPROTEIN (A) PREDICT SYMPTOMATIC BYPASS GRAFT DISEASE ON FOLLOW-UP FOLLOWING CORONARY ARTERY BYPASS SURGERY Harris M. , Shammass N.W., Jerin M. (Davenport, IA, USA)	41
38.	EFFECT OF AGGRESSIVE LIPID LOWERING THERAPY ON LIPOPROTEIN SUBCLASS LEVELS Kerwin T. , Fiedler B., Geohas C., Bai C., Gupta A., Feinstein S. (Chicago, IL, USA)	42
39.	INCREASED RISK (PATTERN B CHOLESTEROL) FOR ISCHEMIC HEART DISEASE DESPITE MEETING CURRENT NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III TREATMENT GUIDELINES Geohas C., Kerwin T. , Bai C., Patel S., Macioch J., Feinstein S. (Chicago, IL, USA)	42
40.	THE CASE OF COEXISTENCE OF DIABETES MELLITUS, HYPERLIPIDEMIA, SHORT STATURE AND HYPOGONADISM (LYNCH SYNDROME) Nikonova T.V. , Smirnova O.M., Dedov I.I. (Moscow, Russia)	42
41.	SIMVASTATIN SIGNIFICANTLY RAISES HDL-C IN PATIENTS WITH TYPE 2 DIABETIC DYSLIPIDEMIA AND LOW HDL-C Miller M., Dobbs A., Borisute H., Yuan Z., Ramsey K., Gergich K., Spigle W., Battisti W., Palmisano J. (Baltimore, MD and West Point, PA, USA)	42

Poster No.		Abstract Book Page Ref.
42.	ANY AMOUNT OF HYPERGLYCEMIA IS PREDICTIVE FOR VASCULAR EVENTS Aczel S., Saely C.H. , Marte T., Langer P., Drexel H. (Feldkirch, Austria)	43
43.	SERUM LEVELS OF LIPOPROTEIN(A) ARE LOW AND NOT PREDICTIVE FOR SURVIVAL AND VASCULAR EVENTS IN PATIENTS WITH DIABETES MELLITUS TYPE 2 REFERRED TO CORONARY ANGIOGRAPHY Saely C.H. , Aczel S., Marte T., Langer P., Drexel H. (Feldkirch, Austria)	43
44.	RISK FACTORS FOR CEREBRAL INFARCTION AND CORONARY EVENTS IN JAPANESE MEN: THE KYUSHU LIPID INTERVENTION STUDY (KLIS) Sasaki J. , Iwashita M., Kono S., Arakawa K. (Fukuoka, Japan)	43
45.	ADVANCED LIPOPROTEIN TESTING BY NMR, AND CAROTID ULTRASOUND PREDICT PREMATURE CORONARY HEART DISEASE Akosah K., Schaper A. , Barnhart S. (La Crosse, WI, USA)	43
46.	LDL OXIDATIVE MODIFICATIONS IN TYPE 2 DIABETES: NO ASSOCIATIONS WITH CAROTID IMT Scheffer P.G. , Henry R.M.A., Wever E.J.M., van Rooij G.J., Bos G., Heine R.J., Dekker J.M., Diamant M., Stehouwer C.D.A., Bouter L.M., Nijpels G., Blankenstein M.A., Teerlink T. (Amsterdam, The Netherlands)	44
47.	PLASMA LIPIDS IN PATIENTS WITH SEVERAL DEGREE OF DIABETIC NEPHROPATHY Akbarov Z.S., Shamansurova Z.M. , Kasimov U.A. (Tashkent, Uzbekistan)	44
48.	CARDIOVASCULAR RISK FACTOR PROFILE IN SUBJECTS WITH DIABETES MELLITUS Downey P., Anwar A., McAteer S., Alrawi M., Tormey W., Healy M.L., O'Shea L.A., Sreenan S. (Dublin, Ireland)	44
49.	CAPILLARY AND VENOUS TRIGLYCERIDES (Tg) IN TYPE 2 DIABETIC PATIENTS de la Vega C., Ruiz Y de P., Escalona F., Rioja J., Ariza M.J., González T., Valdivielso P. , González P. (Málaga, Spain)	44
50.	POSTPRANDIAL TRIGLYCERIDES AS MARKER OF CLINICAL VASCULAR DISEASE IN TYPE 2 DIABETES del Mar Gil M., Escalona F., Fernández-Vargas D., Valdivielso P. , González P. (Málaga, Spain)	45

POSTER SESSION 7

◆
**TRIGLYCERIDE-RICH LIPOPROTEINS,
INFLAMMATION, AND ATHEROSCLEROSIS**

Poster No.		Abstract Book Page Ref.
51.	RELATIONSHIP BETWEEN ATORVASTATIN INDUCED REDUCTIONS IN ATHEROGENIC LIPOPROTEINS AND C-REACTIVE PROTEIN Joss N., Stewart G., Boulton-Jones J.M., Deighan C.J., Packard C.J., Caslake M.J. (Glasgow, UK)	45
52.	SHORT AND LONG TERM CHANGES IN INFLAMMATORY MARKERS ASSOCIATED WITH PRE-ECLAMPSIA Freeman D.J. , McManus F., Brown E.A., Cherry L., Norrie J., Clark P., Walker I.D., Sattar N., Greer I.A. (Glasgow and Dundee, UK)	45
53.	SIMULTANEOUS QUANTIFICATION OF MULTIPLE APOLIPOPROTEINS IN BIOLOGICAL SAMPLES USING XMAP TECHNOLOGY Ji S. , Witherbee B., Mistry J., Ryan R. (St. Charles and St. Louis, MO, USA)	45
54.	APPLICATION OF LASER FOR THE CORRECTION OF TRIGLYCERIDE LEVEL IN OLD AGED PATIENTS WITH GASTROINTESTINAL DISORDERS Karpenko O.M. , Tereshina E.V., Serova L.D., Ivanenko T.V. (Moscow, Russia)	46
55.	HYPERHOMOCYSTEINAEMIA, DYSLIPIDAEMIA CONNECTION WITH BLOOD PRESSURE AND HEART RATE VARIABILITY IN HAEMODIALYSED PATIENTS Löcsey L. , Szlanka B., Dán A., Kiszgáti M., Borbás B., Ménes I. (Debrecen, Hungary)	46
56.	NUTRITIONAL ASSESSMENT IN HAEMODIALYSIS PATIENTS Löcsey L. , Borbás B., Szlanka B., Kiszgáti M., Dán A., Ménes I. (Debrecen, Hungary)	46
57.	RAPID ULTRACENTRIFUGATION METHOD FOR THE ISOLATION OF HDL, HDL ₂ AND HDL ₃ McEneny J. , McPherson P., McKibben B., Young I.S. (Belfast, UK)	46

Poster No.		Abstract Book Page Ref.
58.	VLDL AND LDL OXIDATION: THE IN VITRO AND IN VIVO EFFECT OF FOLIC ACID AND 5-METHYLTETRAHYDROFOLATE (5-MTHF) McEneny J. , Couston C., McKibben B., Young I.S., Woodside J.V. (Belfast, UK)	47
59.	PROTECTION OF PARAOXONASE1 BY LIPIDS Sok D.-E. , Su N.D. (Taejon, Korea)	47
60.	VLDL POTENTIATES LPS-INDUCED TNF EXPRESSION IN MACROPHAGES Stollenwerk M. , Schiopu A., Fredrikson G.N., Dichtl W., Nilsson J., Ares M.P.S. (Malmö, Sweden)	47
61.	EFFECTS OF DIETARY N-3 AND N-6 PUFA INTAKE ON ATHEROMATOUS PLAQUE STABILITY Thies F. , Garry J.M., Yaqoob P., Rerkasem K., Chulakadabba A., Williams J., Shearman C.P., Gallagher P.J., Calder P.C., Grimble R.F. (Aberdeen and Southampton, UK)	47
62.	FUNCTIONAL ROLE AND DIAGNOSTIC VALIDITY OF APOLIPOPROTEIN(a) AND LP(a) SERUM CONTENTS Ameluchkina V.A., Titov V.N. (Moscow, Russia)	48
63.	PLASMA TRIGLYCERIDES DURING LIPID LOAD IN WOMEN WITH FUNCTIONAL HYPERANDROGENY Zykova T.A. , Bahtina Z.E., Strelkova A.V. (Arkhangelsk, Russia)	48

POSTER SESSION 8

◆
FATTY ACIDS

Poster No.		Abstract Book Page Ref.
64.	OLEIC ACID REVERSES THE DETRIMENTAL EFFECTS OF SATURATED FATTY ACIDS ON CACO-2 CELLS Bateman P.A. , Yaqoob P., Williams C.M. (Reading, UK)	48
65.	RAPID SUPPRESSION OF APO A-IV AND APO A-V GENE EXPRESSION IN RAT LIVER BY DIETARY n-3 POLYUNSATURATED FATTY ACIDS Dorfmeister B. , Hagerty B., Krenn B., Eder C., Stangl H., Strobl W. (Vienna, Austria)	48
66.	MANAGEMENT OF ELEVATED LIPOPROTEIN(a) VIA INITIAL DIETARY MODIFICATION AND OMEGA 3 FATTY ACID SUPPLEMENTS: A CASE REPORT Helmbold A.F. (San Antonio, TX, USA)	49
67.	POTENTIAL ROLE OF ENDOTHELIAL LIPASE IN ENDOTOXIN SHOCK Kojima Y. , Hirata K., Ishida T., Yokoyama M., Quertermous T. (Kobe, Japan and Stanford, CA, USA)	49
68.	AN INFLUENCE OF FISH USAGE ON SERUM TRIGLYCERIDES OF ELDERLY MALES Luksiene D.K. , Cerniauskiene L.R., Margeviciene L., Domarkiene S., Varskeviciene Z. (Kaunas, Lithuania)	49
69.	C-REACTIVE PROTEIN AND OMEGA 3 FATTY ACIDS IN PATIENTS WITH A PREVIOUS MYOCARDIAL INFARCTION Madsen T. , Svensson M., Christensen J.H., Schmidt E.B. (Aalborg, Denmark)	49
70.	A UNIQUE FEATURE OF PC-CHOLESTEROL COMPLEX IN ATHEROMA CORRELATES FOAM CELL RUPTURE Mori M. , Itabe H., Saijo M., Asano T., Yoshizumi M., Takano T. (Kanagawa and Hiroshima, Japan)	50

Poster No.		Abstract Book Page Ref.
71.	LIPIDS FROM NATURAL GAS-UTILISING BACTERIA (BACTERIAL PROTEIN) REDUCE PLASMA CHOLESTEROL CONCENTRATIONS IN MINK COMPARED WITH SOYBEAN OIL Müller H. , Skrede A. (Aas, Norway)	50
72.	POSITIVE EFFECT OMEGA-3 ACIDS IN PATIENTS WITH LIVER DISEASE OF DIFFERENT AETIOLOGY Panchenco V.M. , Isaev V.A., Lyutova L.V., Karabasova M.A. (Moscow, Russia)	50
73.	THE REMOTE EFFECT OF THE SHORT-TERMED TRIGLYCERIDEMIA INDUCED BY NONIONIC DETERGENT Tereshina H. (Moscow, Russia)	50
74.	ATHEROSCLEROSIS AS A CONFORMATION DISEASE. COMMON MECHANISM OF THE PHYSICO-CHEMICAL EFFECTS OF MEDITERRANEAN DIET, ESSENTIAL FATTY ACIDS, FIBRATES AND PROBUCOL Titov V.N. (Moscow, Russia)	51
75.	BLOCKADE OF THE UPTAKE OF SATURATED FATTY ACIDS IN THE FORM OF TRIGLYCERIDES AS THE BASIS FOR INSULIN RESISTANCE Titov V.N. (Moscow, Russia)	51
76.	DOUBLE BONDS OF FATTY ACIDS IN SERUM LIPIDS OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA Lisitsyn D.M., Titov V.N. , Nezhdanova I.P., Kukharchuk V.V. (Moscow, Russia)	51
77.	PARALLEL AND CONSECUTIVE TRANSPORT OF SATURATED AND POLYENIC FATTY ACIDS BY LIPOPROTEINS. PRIMARY AND SECONDARY ATHEROSCLEROSIS Titov V.N. , Tischenkov V.G. (Moscow, Russia)	51
78.	TRANSFORMATIONS OF APOB-48 AND APOB-100 LIPOPROTEINS IN THE TRANSPORT OF SATURATED AND POLYENIC FATTY ACIDS. DIAGNOSTIC VALIDITY OF LIPOPROTEIN ELECTROPHORESIS Kotkina T.I., Titov V.N. (Moscow, Russia)	52
79.	HYPOTRIGLYCERIDEMIC EFFECT OF HIGH MONOUNSATURATED FAT INTAKE IS NOT MEDIATED BY DECREASED VLDL TRIGLYCERIDE SYNTHESIS Wilke M.S. , Ryan E.A., French M.A., Jumpsen J., Goh Y.K., Clandinin M.T. (Edmonton, AB, Canada)	61

POSTER SESSION 9

◆
DRUGS AFFECTING LIPID METABOLISM

Poster No.		Abstract Book Page Ref.
80.	HYPOTRIGLYCERIDEMIC EFFECT OF ATORVASTATIN AND SIMVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE, COMBINED HYPERLIPIDEMIA AND TYPE 2 DIABETES MELLITUS Akhmedzhanov N.M. , Vasutina E.I., Metelskaya V.A., Oganov R.G. (Moscow, Russia)	52
81.	RELATION BETWEEN TRIGLYCERIDES, VARIOUS LIPIDS AND CAROTID INTIMA-MEDIAL LAYER IN PATIENTS WITH STENOCARDIA UNDER LONG-TERM TREATMENT WITH ZOCOR AND LIPRIMAR Akhvlediani M. , Balavadze M., Martiashvili M., Gachechiladze D. (Tbilisi, Georgia)	52
82.	SUSTAINED RELEASE NIACIN AND PHYSICAL TRAINING PROGRAM IN REHABILITATION OF PATIENTS WITH PRIOR MYOCARDIAL INFARCTION Aronov D.M. , Keenan J., Krasnitsky V.B., Novikova N.K., Olferiev A.M., Perova N.V., Vygodin V.A. (Moscow, Russia and Minneapolis, MN, USA)	52
83.	EFFECT OF AN ANTI-INFLAMMATORY DRUG (PIROXICAM) ON SOME BIOCHEMICAL FACTORS AND DEVELOPMENT OF EXPERIMENTAL ATHEROSCLEROSIS IN RABBITS Asgary S. , Naderi Gh., Dashti Gh., Paknahad Z. (Isfahan, Iran)	53
84.	DOSE-DEPENDENT EFFECTS OF PRAVASTATIN TREATMENT ON COAGULATIVE AND INFLAMMATORY PARAMETERS Avellone G. , Di Garbo V., Bono M., De Simone R., Raneli G., Licata G. (Palermo, Italy)	53
85.	TIME COURSE TO ACHIEVE NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL GOALS WITH NIACIN EXTENDED-RELEASE LOVASTATIN AS INITIAL THERAPY VERSUS ATORVASTATIN AND SIMVASTATIN Bays H.E. , McGovern M.E., Simmons P.D., Wu T.-Y. (Louisville, KY, USA)	53

Poster No.		Abstract Book Page Ref.
86.	LIPID-MODIFYING EFFECTS OF ROSUVASTATIN AND OTHER STATINS: RESULTS FROM MERCURY I STUDY Blasetto J.W. , Schuster H. (Wilmington, DE, USA and Berlin, Germany)	53
87.	MECHANISMS OF THE HYPOTRIGLYCERIDEMIC ACTION OF LOVASTATIN IN RAT Bocos C. , López-Pérez I.C., Relaño E., Herrera E. (Madrid, Spain)	54
88.	BENEFICIAL EFFECTS OF LONG-TERM ATORVASTATIN TREATMENT IN PATIENTS WITH STABLE ANGINA Chumburidze Sh.D. , Kipshidze N.N. (Tbilisi, Georgia)	54
89.	DOSE-EFFECT RELATIONSHIP OF FENOFIBRATE IN PATIENTS WITH THE METABOLIC SYNDROME Crimet D. , Mercier F., Ansquer J.C., Salomon H., Sirugue I. (Daix, France)	54
90.	THE ROLE OF SIMVASTATIN IN ACUTE PHASE OF MYOCARDIAL INFARCTION. A RETROSPECTIVE STUDY ON SHORT AND LONG TERM BENEFITS Esposito N. , Pergola V., D'Andrea A., Liccardo B., Alfieri A., Ferraro M., Maglione A., Cerino I. (Naples, Italy)	54
91.	MECHANISM OF ACTION OF NIACIN ON TRIGLYCERIDE SYNTHESIS IN HEPATOCYTES Ganji S.H. , Xing Y., Kamanna V.S., Kashyap M.L. (Long Beach and Irvine, CA, USA)	55
92.	ROSUVASTATIN COMPARED ACROSS DOSES WITH ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FOR MODIFYING LIPIDS: RESULTS FROM THE STELLAR STUDY Gold A. , Blasetto J.W., Jones P.H. (Wilmington, DE and Houston, TX, USA)	55
93.	EFFECT OF FENOFIBRATE ON LIPOPROTEIN SUBCLASSES AND INFLAMMATION MARKERS IN PATIENTS WITH HYPERTRIGLYCERIDEMIA Ikewaki K. , Tohyama J., Kido T., Mochizuki S. (Tokyo, Japan)	55
94.	STATINS, CYTOKINES AND MACROPHAGE FOAM CELL FORMATION Lindholm M.W. , Nilsson J. (Malmö, Sweden)	55
95.	THE ANTI-INFLAMMATORY EFFECT OF ROSIGLITAZONE VS. PIOGLITAZONE ON CARDIO-CRP LEVELS IN PATIENTS WITH TYPE 2 DIABETES Trinh C., Litvin Y. (Englewood, NJ, USA)	56
96.	CHANGE OF LIPIDPEROXIDATION AFTER FLUVASTATIN TREATMENT IN RENAL TRANSPLANTED PATIENTS Löcsey L. , Seres I., Asztalos L., Dán A., Kisgáti M., Paragh Gy. (Debrecen, Hungary)	56

Poster No.		Abstract Book Page Ref.
97.	INSULIN SENSITIZER ROSIGLITAZONE RESTORES RENAL DOPAMINE D1-RECEPTOR FUNCTION AND LOWERS BLOOD PRESSURE IN OBESE ZUCKER RATS Lokhandwala M.F. , Umrani D.N., Hussain T., Banday A.A. (Houston, TX, USA)	56
98.	COMPARISON OF 120 MG OF EXTENDED-RELEASE LOVASTATIN VERSUS 20 MG ATORVASTATIN Lukacsko P. , Niecestro R., Walters E., Cecic M., Friedhoff L. (Hackensack, NJ, USA)	56
99.	2-0-(STANOXYPHOSPHORYL) ASCORBATES, DISODIUM SALT, FM-VP4, DECREASES BLOOD LIPIDS AND BODY WEIGHT WITHOUT OBSERVED TOXICITY Lukic T. , Pritchard P.H., Wasan K.M. (Vancouver, BC, Canada)	57
100.	BENEFIT DECREASE OF GLOBAL RISK ON COMBINED ANTIHYPERTENSIVE AND STATIN THERAPY IN PATIENTS WITH METABOLIC SYNDROME Mamedov M.N. (Moscow, Russia)	57
101.	INFLUENCE OF SIMVASTATIN ON SERUM LEVELS OF INFLAMMATION MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Koval D.M., Mankovsky B.N. (Kiev, Ukraine)	57
102.	THE EFFECTS OF SIMVASTATIN ON ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIC CHILDREN McNeal C.J. , Wilson D.P., Mixon T., MacFarlane R.D., Meininger C. (Temple, TX, USA)	57
103.	SOME RESULTS OF FLUVASTATIN TREATMENT DURING VARIOUS COURSES OF TREATMENT Snitko V., Kulsha L., Vdovichenko V.P., Korshak T.A., Muhammad J. , Gasak L., Semashko V., Stankevich P.B. (Grodno, Belarus)	58
104.	ANTIOXIDANT EFFECTS OF SOME AMINO ACID ON LDL OXIDATION Naderi Gh. , Asgary S., Sarafzadegan N., Shirvani H., Gharipour M. (Isfahan, Iran)	58
105.	EFFECT OF ANTHOCYANINS FROM CHOKEBERRY (ARONIA MELANOCARPA) ON BLOOD PRESSURE, INFLAMMATORY MEDIATORS AND CELL ADHESION MOLECULES IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) Naruszewicz M. , Dluzniewski M., Laniewska I., Pikto-Pietkiewicz W., Millo B., Zapolska-Downar D. (Szczecin and Warsaw, Poland)	58
106.	CIPROFIBRATE EFFECT ON PARAOXONASE ACTIVITY Paragh Gy. , Seres I., Harangi M., Erdei A., Audikovszky M., Debreczeni L., Kovácsay A., Illyés L., Pados Gy. (Debrecen and Budapest, Hungary)	58

Poster No.		Abstract Book Page Ref.
107.	<p>CHANGES OF TRIGLYCERIDE LEVELS IN PATIENTS WITH HYPERHOMO-CYSTEINEMIA AFTER TREATMENT WITH FOLIC ACID</p> <p>Paximadas S., Pagoni S., Tentolouris N., Kanellas K., Moutafis D., Gialernios Th., Ioakeimidis N. (Athens, Greece)</p>	59
108.	<p>AGGRESSIVE MANAGEMENT OF DYSLIPIDEMIA IN A COLLABORATIVE-CARE PRACTICE MODEL</p> <p>Ryan M.J., Gibson J., Simmons P., Stanek E. (Bryn Mawr, PA and Miami, FL, USA)</p>	59
109.	<p>PLASMA LIPID DISTURBANCES AT THE SEVERAL STAGE OF METABOLIC SYNDROME</p> <p>Shamansurova Z.M., Akhmedova M., Akbarov Z.S., Norimova G.G., Sikiotova I.B. (Tashkent, Uzbekistan)</p>	59
110.	<p>HYPOLIPIDEMIC EFFECTS OF FLUVASTATIN AND ITS COMBINATION WITH NIACIN</p> <p>Snitko V., Kulsha L., Vdovichenko T.V., Korshak T.A., Muhammad J., Smolyar N. (Grodno, Belarus)</p>	59
111.	<p>CHANGES IN SERUM LIPOPROTEINS IN WOMEN USING ORAL CONTRACEPTIVES</p> <p>Taborsky L., Dvorakova J., Bocanova E., Kempe V. (Prague, Czech Republic)</p>	60
112.	<p>HAEMOSTASIS PARAMETERS CHANGES DURING ATORVASTATIN AND SIMVASTATIN THERAPY IN CORONARY HEART DISEASE PATIENTS WITH COMBINED HYPERLIPIDEMIA AND TYPE 2 DIABETES MELLITUS</p> <p>Vasutina E.I., Metelskaya V.A., Akhmedzhanov N.M., Ratnikova L.A., Oganov R.G. (Moscow, Russia)</p>	60
113.	<p>PUTATIVE BIOMARKERS TO DISCRIMINATE THE PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR ALPHA/GAMMA EFFECTS OF FENOFIBRATE AND ROSIGLITAZONE IN NORMAL VOLUNTEERS</p> <p>Wagner J.A., Combs T., Weiss S., Larson P.J., Miller J.L., Doebber T.W., Wu M.S., Gottesdiener K.M., Moller D.E., Scherer P.E., Gertz B.J. (Rahway, NJ, Bronx, NY and San Diego, CA, USA)</p>	60
114.	<p>PREVALENCE OF ARTERIAL HYPERTENSION IN POLAND IN 2002, AND ITS INFLUENCE ON RISK OF MYOCARDIAL INFARCTION</p> <p>Zdrojewski T., Bandosz P., Szpakowski P., Konarski R., Zagozdzon P., Bautembach S., Thomsen T., Wyrzykowski B. (Gdansk and Sopot, Poland and Copenhagen, Denmark)</p>	60